Cargando…
Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment
Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactiv...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409366/ https://www.ncbi.nlm.nih.gov/pubmed/36012657 http://dx.doi.org/10.3390/ijms23169394 |
_version_ | 1784774833649745920 |
---|---|
author | Oriuchi, Noboru Endoh, Hideki Kaira, Kyoichi |
author_facet | Oriuchi, Noboru Endoh, Hideki Kaira, Kyoichi |
author_sort | Oriuchi, Noboru |
collection | PubMed |
description | Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactive cells such as activated T-cells and macrophages, which show increased glucose metabolism and apparent progression on morphological imaging. Cellular metabolism and function are critical determinants of the viability of active cells in the tumor microenvironment, which would be novel targets of therapies, such as tumor immunity, metabolism, and genetic mutation. Considering tumor heterogeneity and variation in therapy response specific to the mechanisms of therapy, appropriate response evaluation is required. Radiomics approaches, which combine objective image features with a machine learning algorithm as well as pathologic and genetic data, have remarkably progressed over the past decade, and PET radiomics has increased quality and reliability based on the prosperous publications and standardization initiatives. PET and multimodal imaging will play a definitive role in personalized therapeutic strategies by the precise monitoring in future cancer therapy. |
format | Online Article Text |
id | pubmed-9409366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94093662022-08-26 Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment Oriuchi, Noboru Endoh, Hideki Kaira, Kyoichi Int J Mol Sci Review Evaluation of cancer therapy with imaging is crucial as a surrogate marker of effectiveness and survival. The unique response patterns to therapy with immune-checkpoint inhibitors have facilitated the revision of response evaluation criteria using FDG-PET, because the immune response recalls reactive cells such as activated T-cells and macrophages, which show increased glucose metabolism and apparent progression on morphological imaging. Cellular metabolism and function are critical determinants of the viability of active cells in the tumor microenvironment, which would be novel targets of therapies, such as tumor immunity, metabolism, and genetic mutation. Considering tumor heterogeneity and variation in therapy response specific to the mechanisms of therapy, appropriate response evaluation is required. Radiomics approaches, which combine objective image features with a machine learning algorithm as well as pathologic and genetic data, have remarkably progressed over the past decade, and PET radiomics has increased quality and reliability based on the prosperous publications and standardization initiatives. PET and multimodal imaging will play a definitive role in personalized therapeutic strategies by the precise monitoring in future cancer therapy. MDPI 2022-08-20 /pmc/articles/PMC9409366/ /pubmed/36012657 http://dx.doi.org/10.3390/ijms23169394 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Oriuchi, Noboru Endoh, Hideki Kaira, Kyoichi Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title | Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title_full | Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title_fullStr | Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title_full_unstemmed | Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title_short | Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment |
title_sort | monitoring of current cancer therapy by positron emission tomography and possible role of radiomics assessment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409366/ https://www.ncbi.nlm.nih.gov/pubmed/36012657 http://dx.doi.org/10.3390/ijms23169394 |
work_keys_str_mv | AT oriuchinoboru monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment AT endohhideki monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment AT kairakyoichi monitoringofcurrentcancertherapybypositronemissiontomographyandpossibleroleofradiomicsassessment |